Colinz Laboratories Ltd. shows concerning metrics in growth and profitability compared to its peers in the Pharmaceuticals & Drugs industry, with no revenue or EPS growth, while its peers exhibit strong performance in these areas. It stands out as a potential value pick due to its low market price in comparison to its lack of financial metrics, but overall, it is financially weak.

• • Colinz has 0% revenue and EPS growth, indicating stagnation.
• • Sun Pharmaceutical and Cipla are the most profitable companies with high ROE and EPS.
• • Mankind Pharma shows impressive growth metrics, making it a strong contender in the sector.
• • Colinz is undervalued in terms of its price-to-earnings ratio, but lacks profitability and growth.